There are two voluntary center-accrediting organizations in the USA, the Foundation for the Accreditation of Cellular Therapy (FACT) and core Clinical Trial Network (CTN) certification, that are thought to improve and ensure hematopoietic cell transplantation (HCT) center quality care and certify clinical excellence. We sought to observe whether there are differences in outcomes between HLA-matched and -mismatched HCT by CTN and FACT status. Using the 2008-2010 Center for International Blood & Marrow Transplant Research data we created three center categories: non-FACT centers (24 centers), FACT-only certified centers (106 centers) and FACT and core clinical trial network (FACT/CTN) certified centers (32 centers). We identified patient characteristics within these centers and the relationship between FACT certification and survival. Our cohort consisted of 12 993 transplants conducted in 162 centers. After adjusting for patient and center characteristics we found that FACT/CTN centers had consistently superior results relative to non-FACT and FACT-only centers (P o 0.05) especially for more complex HCT. However, non-FACT centers were comparable to FACT-only centers for matched related and unrelated patients. Although FACT status is an important standard of quality control that begins to define improved OS, our results indicate that FACT status alone is not an indicator for superior outcomes.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) is a complex treatment for several hematological disease groups. Finding suitable related or unrelated donors has increasingly become more common in the last decade with the proliferation of HCT centers and ease of access to donor registries. Clinical best practice dictates that, whenever possible, HLA-matched related or unrelated donors are preferable for reducing the risk of posttransplant complications and infections and improving the chances for long-term survival. [1] [2] [3] [4] [5] Created to establish and certify clinical excellence in process and outcomes within HCT centers in the USA, the Foundation for the Accreditation of Cellular Therapy (FACT) is a nonprofit entity cofounded by the International Society for Cellular Therapy and the American Society of Blood and Marrow Transplantation in 1996. 6 Specific standards for accreditation include a minimum of five HCTs annually, guidelines for HCT center laboratories and clinical oversight and methodologies for HLA typing and processing. Accreditation is awarded after successful documentation of compliance with the current FACT standards and payment of an annual fee. A team of clinical inspectors carries out annual on-site inspections. 6 In addition to facility certification, FACT publishes quality guidelines that are readily available to all centers.
FACT centers have a reputation as centers of excellence that exert adequate quality control over the entire HCT process. Non-FACT centers may adhere to evidence-based practice and nonaccredited levels of excellence in processes and outcomes. However, payers and providers do not recognize non-FACT accredited centers in the USA as experienced centers with fully developed clinical treatment protocols. 7, 8 There is a core assumption that FACT center accreditation improves and ensures HCT center quality care that is unattainable by other nonaccredited centers.
Certifying and accrediting centers of excellence is not a novel approach to overseeing and underscoring standards of excellence and health-care quality. There is a broad literature exploring whether there are differences in the process and outcomes at academic health centers (AHC), accredited centers of excellence, teaching hospitals and the National Cancer Institute's Comprehensive Cancer Centers (NCICCC). [8] [9] [10] [11] [12] [13] [14] [15] Results of these analyses have been mixed. For example, using the national Medicare database, Birkmeyer et al. 9 conducted an analysis of 51 NCICCC and 6 cancer procedures. Birkmeyer et al. 9 found that NCI designated cancer centers had lower surgical mortality rates than those treated at comparably high-volume hospitals, but had similar long-term survival rates. Analyses performed in Europe by Gratwohl et al. 15 showed that patient outcomes were systematically better when the transplantation center was at a more advanced phase of Joint Accreditation Committee International Society (JACIE) for Cellular Therapy and the European Group for Blood and Marrow Transplantation accreditation. Late JACIE adopters and centers in the process of applying for accreditation did not demonstrate similar superiority. Overall, Gratwohl et al. 15 found that the process of JACIE accreditation and the introduction of a clinical quality management and guidelines were associated with improved HCT outcomes. Other literature that analyzed process measures of care or risk-adjusted mortality rates found differences in quality between major teaching hospitals and nonteaching hospitals across several cancer groups. [16] [17] [18] [19] [20] The HCT literature that focuses on center characteristics and FACT certification is limited. Several transplant center characteristics have been associated with increased survival. In a descriptive study, Majhail et al. 20 found that there was significant practice variation, such as physician workforce and clinician approach to transplantation for hematologic disorders. Using the Center for International Blood & Marrow Transplant Research (CIBMTR) data from 1998 to 2000, Loberiza et al. 21 found significant survival differences for patients receiving allogeneic HCT in centers with one or more favorable center-related factors, such as contacting patients for after-hours call and medical school affiliation. However, Loberiza et al. 21 did not find an association between factors that might be expected to correlate with increased levels of survival such as FACT accreditation.
In addition to FACT accreditation, centers hold a variety of other credentials, including NCICCC, AHC status and Center of Excellence Designation by Medical Insurance Plans. These are highly correlated with each other. In 2001, with the support of the National Cancer Institute and the National Heart, Lung and Blood Institute, the Blood and Marrow Transplant Clinical Trials Network (CTN) was established. 22 Currently, there are 32 centers that participate as 'core' centers within the USA with the goal of conducting multicenter trials to address clinical issues in HCT and offer trial participation to patients in all regions of the USA.
The HCT literature has previously found no significant differences between FACT and non-FACT centers. As FACT accreditation has become more common among centers (~90% of USA HCT centers are accredited), we created a third center category of FACT and core CTN centers (FACT/CTN) in order to determine if FACT/CTN centers demonstrated a high level of excellence. In addition, in order to account for patient complexity, we sought to determine if accreditation had any impact on the survival of HLA-mismatched HCT. Specifically, our goal is to broaden the scope of the accreditation and HCT literature by assessing if there are differences in outcomes between HLAmatched and -mismatched HCT by FACT and CTN status.
MATERIALS AND METHODS

Data source
The data presented here were obtained from the Statistical Center of the CIBMTR located at the Medical College of Wisconsin and the National Marrow Donor Program. The CIBMTR is partially supported by a Grant, U24-CA76518, from the National Institutes of Health, and by the Health Resources and Services Administration. CIBMTR comprises a voluntary working group of 4450 transplantation centers worldwide that contribute detailed data on consecutive HCT to its statistical center. In addition, the CIBMTR holds the contract for the Stem Cell Therapeutic Outcomes Database part of the CW Bill Young Transplantation Program from the Human Resources and Services Administration. As a part of this program, all transplant centers in the USA are mandated to report clinical outcome data for allogeneic HCT to the CIBMTR. We obtained a de-identified data set from CIBTMR. The analysis has not been reviewed by the CIBMTR. Our study was deemed exempt from review by the Human Subjects Committee of the University of Minnesota's Institutional Review Board.
FACT center categories and center characteristics
We linked our CIBMTR data to an online, publically available FACT organizational list and the core CTN certified center status list 22, 23 and created three center categories: non-FACT centers (24 centers), FACT-only accredited centers (106 centers) and FACT and core CTN certified (FACT/ CTN) centers (32 centers). FACT/CTN centers are accredited by FACT but are also a part of HCT leadership as they conduct multicenter trials to address clinical issues in HCT. In addition to FACT and CTN status, we recorded several other center characteristics including 10 Department of Health and Human Services (HHS) regions and center volume quartiles.
Patient variables
The data set included allogeneic transplant recipients 18 years or older who received transplants from 1 January 2008 to 31 December 2010. We included patients who received a PBSC or BM graft from HLA matched or mismatched, related or unrelated donors; umbilical cord blood transplant recipients were excluded. All diagnoses were considered.
Variables considered in the analysis included the Karnofsky performance status, which is used to determine the functional status of a recipient and can range from 0 to 100. A Karnofsky performance score of 90-100 categorizes patients with the ability to carry on normal activity and no special care is needed. 24 CIBMTR categorized Karnofsky scoring as a dichotomous variable of 90-100, and ⩽ 80. Coexisting disease is a binary category of diseases collected by CIBMTR. CIBMTR codes HCT patients with any of 18 comorbidities as coexisting disease present. 25 We included patients that had missing coexisting disease information (406 patients). We initially considered four donor and transplant type categories-HLAmatched related, HLA-mismatched related, HLA-matched unrelated and HLA-mismatched unrelated. The analysis results for HLA-matched related and unrelated donor HCT and those for HLA-mismatched related and unrelated donor HCT were similar, and hence we combined our matched related and unrelated patients into one category and our mismatched related and unrelated patients into a second category.
Statistical analysis
We evaluated differences in FACT center status and patient characteristics across all years of transplantation. We evaluated the differences in FACT center status and patient characteristics using the chi-square test. After assessing unadjusted relationships we used logistic regression to examine the association between the relative odds of mismatched related or unrelated HCT (yes/no), patient demographics and FACT/CTN status. Finally, we evaluated the association between FACT certification and 3-year hazard of death using Kaplan-Meier methods and Cox proportional hazards modeling. To capture the interaction between both FACT status and HLA-match category we created an HLA-match category by FACT status variable. To adjust for possible high-volume center effects in our cohort we created a center volume quartile indicator.
In all models, we performed several sensitivity analyses to ensure that the observed effects were not a product of our FACT center classification and modeling decisions. We modeled our cohort with various severity distinctions and disease groups with and without non-FACT centers to ensure that these centers did not distort our results for the two other FACT categories, in which the majority of transplants were performed. We restricted our analyses to high-volume centers to confirm that center volume did not alter the direction of our results. The analyses did not produce results of different magnitude or direction. We also performed separate survival analyses to verify that our proportional hazard ratios were not a product of center regions. Finally, we conducted separate analyses for related and unrelated cohorts. Under all assumptions, conclusions remain unchanged. SAS version 9.3 (SAS Institute, Cary, NC, USA) was used for all analyses. P-values were two-sided with a level of significance of ⩽ 0.05.
RESULTS
Our final cohort consisted of 12 993 transplants conducted in 162 centers. Of these, 24 centers were non-FACT certified (N = 559 transplants), 106 centers were FACT-only certified (N = 5655 transplants), and 32 centers had FACT/CTN status (N = 6779 transplants) ( Table 1) . Most of the patient cohort was classified with a coexisting disease (64%, N = 8279) and 62% had a Karnofsky score 490 (N = 8014). The majority of the patients (66%) were diagnosed with AML and myelodysplastic disorders (MDS) (N = 6263 transplants) or non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) (N = 2320 transplants).
Matched related donors (N = 5349 transplants) or matched unrelated donors (N = 5419 transplants) accounted for 83% of HCTs. The percentage of unrelated transplants ranged from 45% within FACT/CTN centers to 48% in non-FACT centers. Similarly, nearly half of the transplants performed in FACT-only and non-FACT centers were related HCTs (47% and 52% in FACT-only HCT and non-FACT HCT, respectively). When the transplant population was broken down by FACT status and HLA-matched or -mismatched status (Figures 1a and b) , non-FACT centers performed the highest percentage of matched related or unrelated HCT (86%) and FACT/CTN centers performed the Association between FACT status and mortality Unadjusted Kaplan-Meier mortality estimates showed significantly higher 3-year overall mortality among all patients in both non-FACT and FACT-only centers relative to FACT/CTN (Figures 2a-c) .
When we stratified matched and mismatched transplant recipients by center certification status we found that FACT/CTN centers had the lowest 3-year overall mortality among HLAmatched related patients. However, non-FACT and FACT certified centers showed strikingly similar curves for HLA-matched related recipients. Unadjusted Kaplan-Meier mortality estimates showed significantly higher 3-year overall mortality among mismatched related HCTs within FACT-only centers. For the unrelated matched HCT cohort both non-FACT and FACT-only centers had lower 3-year overall mortality than mismatched unrelated HCT recipients.
Adjusted association between FACT status and hazard of death To capture the interaction between both FACT status and HLA-match category we created an HLA-match category by FACT-status variable. After adjusting for patient and center characteristics ( Table 3 ) we found that non-FACT/mismatched HCT patients had the highest adjusted relative hazard of death (adjusted hazard ratio (HR): 2.05; P-value o 0.0001 non-FACT/any mismatch vs non-FACT/matched). However, FACT/matched patients had a higher relative hazard of death relative to non-FACT/matched HCT (adjusted HR: 1.13; P-value = 0.075 FACT/ Matched vs non-FACT/matched). The FACT/CTN superiority trend persisted for mismatched HCT. However, the non-FACT centers performed remarkably similarly to the FACT-only centers for both matched and mismatched patients.
DISCUSSION
In this study we found that FACT/CTN accreditation was most strongly associated with superior overall 3-year survival. Differences in survival by FACT accreditation status were most apparent for more complex HCTs. Non-FACT and FACT-only centers were less likely to perform mismatched HCT relative to FACT/CTN centers. After stratifying our transplant recipients by related and unrelated match categories we found that FACT/CTN centers were more capable of performing complex mismatched HCTs compared with centers with FACT-only and non-FACT accreditation status.
Despite the inferior outcomes of mismatched HCT patients in non-FACT centers relative to FACT-only and FACT/CTN centers, non-FACT and FACT-only centers performed similarly overall in the HLA-matched HCT category. These results suggest that, since FACT's inception nearly two decades ago, FACT accreditation has become ubiquitous among HCT centers and that HCT techniques have consistently improved across all centers irrespective of accreditation status. For example, like Loberiza et al., 8 we found a lack of association between procedure volume and survival (Table 3) . We believe that FACT care processes have been standardized, routinized and disseminated to the point that the learning and improvement that derives from higher volume is no longer a major factor. Our findings are consistent with previous center accreditation literature that finds mixed results. When FACT centers are stratified into distinct categories, FACT/CTN accreditation status does imply superior overall results in the mismatched transplants category. We are limited in our ability to comment on the apparent superiority of FACT/CTN centers because we cannot completely rule out explanations such as observed higher transplant volume or patient case mix. However, based on our sensitivity analysis we do not believe that FACT/CTN centers' superior results are due to volume or case mix. It is possible that the FACT/CTN superiority we observe is due in part to strict inclusion and exclusion criteria into the CTN. If this is the case, we might expect FACT to try and adopt CTN guidelines over time. However, we do not believe that FACT/ CTN superiority is an artifact of a higher proportion of patients within clinical trials as there is a significant advantage for related and unrelated HCT alike. Instead, we hypothesize that one explanation for FACT/CTN superiority is that the nature of the clinical trials conducted in FACT/CTN centers requires higher levels of national clinical collaboration and standardization of protocols. High levels of collaboration in FACT/CTN centers are likely to generate higher levels of innovation and excellence among clinical colleagues.
Although our study provides important implications for center certification initiatives, we acknowledge several data-related limitations. There are additional factors that may explain survival that we did not include in our model. For example, we did not include whether treatment was performed on or off a clinical trial.
The data do not indicate which of our centers participated in trials or which patients were enrolled in trials. We are limited in our ability to account for patient migration as the data do not allow us to track the patient trajectory. It would be possible that a higherrisk patient population would receive HCT in non-CTN centers only after being rejected by the 32 CTN centers. However, this higherrisk population would not explain the similarities we observed for the matched-related HCT between the three groups. If indeed higher-risk patients were more likely to use non-FACT centers, we would expect to see larger differences in survival for related HCT between centers. Finally, the interval between initial diagnosis and transplantation would be an important factor to consider in our analyses. We did not receive data that included this interval, but believe it to be an important factor to consider in future analyses. Unlike Gratwohl et al., 15 we are restricted by our data and were limited in our ability to account for early and late adopters of FACT accreditation. Despite these data limitations, our results highlight differences between FACT centers and the need for additional research to explain the causal mechanisms involved in FACT/CTN superiority.
Our study has important implications for providers, policy makers and patients seeking a transplant center. FACT accreditation has been promoted as a measure of center excellence. For example, FACT accreditation is a factor in the ranking of 'America's Best Hospitals,' and 'America's Best Children's Hospitals,' published annually by US News and World Report. Our results begin to illustrate the variation within FACT categories and also underscore the notion that FACT accreditation alone is not sensitive enough as an indicator to differentiate transplant centers. However, the broader relationship between FACT status and a center's specific HCT-survival rate remains complex, requiring a deeper understanding of the causal mechanisms involved and finding specific factors that could be introduced to all centers to improve outcomes. Learning from the evolution of accredited centers over time will provide policy makers, administrators and payers with information to guide future resource planning quality improvement efforts.
AUTHOR CONTRIBUTIONS
All authors of this research paper have directly participated in the planning, execution, or analysis of the study. All authors of this paper have read and approved the final version submitted.
DISCLAIMER
The contents of this manuscript have not been copyrighted or published previously. The contents of this manuscript are not now under consideration for publication elsewhere. The contents of this manuscript will not be copyrighted, submitted, or published elsewhere while acceptance by the Journal is under consideration. All directly related manuscripts or abstracts, published or unpublished, by one or more authors of this paper have been included with the manuscript submission. As per the data use agreement (DUA), the analysis has not been reviewed or approved by the CIBTMR.
